Rani Therapeutics (RANI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, with voting available online, by phone, mail, or virtually at the meeting.
Shareholders are encouraged to review proxy materials and vote on key proposals before the meeting date.
Voting matters and shareholder proposals
Election of seven nominees to the Board of Directors to serve until the 2027 Annual Meeting.
Ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting or any adjournment.
Board of directors and corporate governance
Seven director nominees listed: Talat Imran, Mir Imran, Dennis Ausiello, Lisa Rometty, Jean-Luc Butel, Abraham Bassan, and Vasudev Bailey.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Rani Therapeutics
- Shareholders will vote on director elections and auditor ratification, with strong governance in place.RANI
Proxy filing16 Apr 2026 - Chugai deal, debt repayment, and clinical progress drive strong financial and pipeline momentum.RANI
Q4 202526 Mar 2026 - RT-114, an oral GLP-1/GLP-2 dual agonist, targets weekly dosing and global obesity market impact.RANI
Investor Update3 Feb 2026 - Oral dual GLP-1/GLP-2 program targets obesity with weekly dosing, Phase 1 starts in 2025.RANI
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Oral biologics platform advances in obesity with strong early data and flexible dosing.RANI
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Oral biologics platform advances with differentiated obesity and immunology programs, strong IP, and new funding.RANI
UBS Global Healthcare Conference 202413 Jan 2026 - Oral biologics platform advances with strong clinical data, key partnerships, and extended cash runway.RANI
Stifel 2024 Healthcare Conference13 Jan 2026 - Oral biologic delivery platform advances with new trials, strong safety, and expanding partnerships.RANI
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - RT-114 prioritized for mid-2025 clinical trial, with strong data and improved financials.RANI
Q4 202426 Dec 2025